InterCure Ltd. recently announced it has entered into a definitive Share Purchase Agreement and a Collaboration Agreement with Cannasoul R&D Ltd. (“Cannasoul”), a globally recognized pioneer in cannabis research and analytics (together, the “Agreements”). The Share Purchase Agreement provides InterCure with a 28% ownership position in Cannasoul on a fully diluted basis and an exclusive path to increase its holdings to 51% within two years, while the Collaboration Agreement formalizes a partnership in research, development, and commercialization of evidence-based cannabis therapeutics.

Notably, the Agreements come as the U.S. cannabis market stands at a historic potential inflection point, with the Trump administration reportedly exploring the rescheduling of cannabis from Schedule I to Schedule III¹ – a transformative regulatory shift that could potentially unlock unprecedented opportunities for international cannabis companies such as InterCure.

As part of the Agreements, Prof. Dedi Meiri, Founder of Cannasoul and a globally recognized cannabis researcher at the Technion – Israel Institute of Technology, is expected to be appointed as the Chairperson as of InterCure’s Scientific Advisory Board to be established by the Company’s board of directors. In this role, Prof. Meiri will assist in integrating Cannasoul’s advanced analytics and research capabilities into InterCure’s pharmaceutical platform, strengthening InterCure’s scientific leadership and accelerating the development of next-generation cannabis-based therapeutics.

“The Agreements mark a significant step in InterCure’s global leadership strategy,” said Alex Rabinovitch, Chief Executive Officer of InterCure. “By combining Cannasoul’s established research capabilities with InterCure’s pharmaceutical-grade platform and under the scientific advisory of Prof. Meiri, we plan to accelerate the development of next-generation cannabis therapeutics, expand our international footprint, and drive long-term value for patients and shareholders alike.”

“Cannasoul’s mission has always been to translate cannabis science into meaningful therapies,” said Prof. Dedi Meiri, Founder of Cannasoul. “Through the Agreements and with the establishment of the Scientific Advisory Board, we believe that we now have the structure, resources, and global reach to move discoveries from the lab to patients faster, with the scientific rigor and scale that meaningful innovation demands.”

The transaction remains subject to customary closing conditions and regulatory approvals.

InterCure Ltd. (dba Canndoc) (Nasdaq: INCR) (TASE: INCR) is a leading fast-growing cannabis company operating outside of North America. Canndoc, a wholly owned subsidiary of InterCure, is Israel’s largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. InterCure leverages its market leading distribution network, best in class international partnerships and a high-margin vertically integrated “seed-to-sale” model to lead the fastest growing cannabis global market outside of North America.

For more information, visit: https://www.intercure.co

Cannasoul R&D is a leading research and analytics laboratory globally recognized as a pioneer in cannabis science. In collaboration with Prof. Dedi Meiri’s laboratory at the Technion – Israel Institute of Technology, Cannasoul has developed advanced analytical and biological-validation platforms to map cannabis compounds and mechanisms of action. Its research spans preclinical and clinical studies across oncology, neurology, and women’s health.